Spyre Therapeutics — Third Quarter 2026 Earnings Summary

Spyre Therapeutics reported positive topline induction data for its three monotherapies (SPY001, SPY002, and SPY003) in the Phase 2 SKYLINE trial for inflammatory bowel disease, completing proof-of-concept for all three agents. While the company initiated a new Phase 2 trial (SKYLIGHT) for hidradenitis suppurativa and raised over $400 million in October 2026, it decided not to advance SPY072 in rheumatic diseases after the drug failed to meet primary endpoints in psoriatic arthritis and axial spondyloarthritis sub-studies. The company holds $1.5 billion in pro forma cash as of September 30, 2026, providing an expected runway into the second half of 2029. Financial results for the third quarter of 2026 showed a net loss of $96.1 million, driven by increased research and development expenses related to manufacturing and clinical trials.